ConforMIS is a medical devices business based in the US. ConforMIS shares (CFMS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.26 – the same closing value as a week prior. ConforMIS employs 295 staff and has a trailing 12-month revenue of around $57.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.26 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $2.24 |
| 200-day moving average | $2.04 |
| Wall St. target price | $2.27 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-5.70 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.26 from 2023-09-14
| 1 week (2024-10-07) | N/A |
|---|---|
| 1 month (2024-09-14) | N/A |
| 3 months (2024-07-14) | N/A |
| 6 months (2024-04-14) | N/A |
| 1 year (2023-10-14) | N/A |
|---|---|
| 2 years (2022-10-18) | 1,634.46% |
| 3 years (2021-10-18) | 93.16% |
| 5 years (2019-10-18) | 2.35 |
Valuing ConforMIS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ConforMIS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ConforMIS's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.21. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ConforMIS's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $57.1 million |
|---|---|
| Gross profit TTM | $23.2 million |
| Return on assets TTM | -27.32% |
| Return on equity TTM | -78.71% |
| Profit margin | -72.73% |
| Book value | $4.07 |
| Market Capitalization | $17.9 million |
TTM: trailing 12 months
We're not expecting ConforMIS to pay a dividend over the next 12 months.
ConforMIS's shares were split on a 1:25 basis on 9 November 2022. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ConforMIS shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for ConforMIS shares which in turn could have impacted ConforMIS's share price.
Over the last 12 months, ConforMIS's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ConforMIS's is 1.4229. This would suggest that ConforMIS's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Conformis, Inc. , a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, iTotal CR, and iTotal PS, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also offers Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Brazil, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.